22:55 IST
NSE
Regulatory Approval
Cipla Regulatory Approval
Cipla received U.S. FDA approval for its Generic Advair Diskus. The product is expected to launch in the U.S. market in Q2 FY 2026-27.
Cipla Ltd
- Share price
- ₹1,327.20
- Market cap
- ₹1,07,221 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 31.8×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 4Employee Stock Options 4Business Update 3Management Change 2Earnings Call 2Acquisition 2Results Update 1Regulatory Approval 1Partnership 1Merger & Restructuring 1Financial Results 1
Time
1 announcement with these filters